Online education plus personalized prevention plan for women at high breast cancer risk.
Official title: Evaluation of a Virtual Risk-reduction Intervention Among Women at Higher Than Average Risk of Breast Cancer in the European MyPeBS Screening Trial
Run by Unicancer · NCT07120087 · Data updated 2026-11-12
This project tests an online webinar and a personalized virtual clinical visit to teach women at high 5-year breast cancer risk how to lower their risk through lifestyle changes and a tailored prevention plan.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years to 74 Years |
| Sex | Women only |
| Enrollment | 1508 (estimated) |
| Sponsor | Unicancer Academic / other |
| Locations | 3 sites (Lyon and 2 other locations) |
| Status | Recruiting |
| Started | February 19, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | June 2027 |
| Registry record updated | July 23, 2026 |
| Trial ID | NCT07120087 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 40 to 74 who participated in MyPeBS, were classified as high or very high 5-year breast cancer risk, can provide consent, and have not been diagnosed with breast cancer are eligible.
✕Probably not a fit
Women who developed breast cancer during MyPeBS follow-up, those at average or low risk, or those unable or unwilling to access or follow online interventions are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
MyPREV is a prospective interventional cohort targeting women identified as high or very high 5-year breast cancer risk within the MyPeBS program using polygenic risk scores and clinical risk factors. The intervention combines a virtual educational webinar with an online personalized clinical visit during which a tailored lifestyle-based prevention plan is created. The study plans to invite 3,016 MyPeBS participants from French and Italian sites and expects about 50% participation (~1,507 women). Outcomes will focus on implementation of prevention measures and engagement with the personalized plan over the follow-up period.
Why it matters
Potential benefit: If successful, the intervention could increase uptake of risk-reducing lifestyle changes and personalized prevention, potentially lowering future breast cancer incidence and the need for intensive treatments.
How similar studies have gone: Lifestyle interventions have demonstrated effectiveness in reducing breast cancer risk, but online personalized prevention programs for high-risk women are a more recent approach with emerging evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Female (whether born female or not) 2. Women aged 40 to 74 years (inclusive) 3. Women who have participated in, or are participating in the MyPeBS study and who fulfilled all the inclusion and non-inclusion criteria for the MyPeBS study. 4. Women able to express their non-opposition to participate in the intervention 5. Women who were assessed as being at high (≥≥1.67% - 5.9%) or very high (≥≥6%) risk of invasive breast cancer at 5 years in the MyPeBS study Exclusion Criteria: 1\. Women who developed a breast cancer during their follow-up in the MyPeBS study
Where it's running
-
Centre Médical et Dentaire de Lyon MGEN
Lyon, France Recruiting -
Gustave Roussy
Villejuif, France Not yet recruiting -
AOU Città della Salute e della Scienza - CPO PiedmontSSD Epidemiologia e Screening
Torino, Italy Not yet recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.